A human study administering tumor infiltrating lymphocytes (TIL) genetically engineered to secrete IL-12 selectively at the tumor site demonstrated limited success due to overwhelming toxicities despite the low doses of TIL administered, about 100-fold lower than conventional TIL therapy in the absence of systemic administration of human recombinant IL-2 [23]. This evidence concerns the gene IL2 and neoplasm.